Recombinase Polymerase Amplification (RPA) as an Isothermal Molecular-Point of Care Test (IM-POCT) for Rapid Identification of P. aeruginosa Among Patients with Respiratory Infection
Molecular Biotechnology · 2025
DOI: 10.1007/s12033-025-01459-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Reza Azizian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Infectious Diseases Research Center (PIDRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Respiratory Tract Infections, Pseudomonas Infections, Recombinases. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Acute Respiratory Infections (ARIs) are a leading cause of pediatric mortality, with Pseudomonas aeruginosa as a key pathogen. This study evaluated Recombinase Polymerase Amplification (RPA)-ELISA for rapid detection of P. aeruginosa in respiratory samples (n = 101). Compared to Real-Time PCR (98.8% sensitivity, 100% specificity), RPA-ELISA showed 97.6% sensitivity and 90% specificity, detecting pathogens at 41 ng/µL within 30 min. The method's simplicity and speed support its use as a screening tool in resource-limited settings, though confirmatory testing remains advised. Respiratory samples (sputum, BAL, throat cultures) were collected from pediatric patients (August-December 2022). P. aeruginosa was identified via culture, biochemical tests, and Real-Time PCR (targeting gyrB). RPA-ELISA was optimized for P. aeruginosa detection using labeled primers/probes. Among 101 samples, 83 (82.2%) were P. aeruginosa. RPA-ELISA demonstrated 97.6% sensitivity (95% CI: 91.7-99.7%) and 90% specificity (95% CI: 55.5-99.7%) compared to Real-Time PCR (98.8% sensitivity, 95% CI: 93.5-100%; 100% specificity, 95% CI: 69.2-100%). The method detected P. aeruginosa at a concentration of 41 ng/µL with a 30-min turnaround time. Positive results were indicated by a color change in the ELISA wells, contrasting with negative controls. RPA-ELISA is a promising IM-POCT for P. aeruginosa, offering high sensitivity and rapid results. It is suitable for resource-limited settings but requires confirmatory testing due to moderate specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Infectious Diseases Research Center (PIDRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
- Biomedical Innovation and Start-Up Student Association, (TUMS), Tehran, Iran.
- Pediatric Infectious Diseases Research Center (PIDRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran. pourakbari@gmail.com.
- Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- Nora Gene Pishro (Knowledge Base Company), Tarbiat Modares University, Tehran, Iran.
Zitieren
APA
Azizian, R., Jafari, E., Pourakabri, B., Mamishi, S., Hosseinkhani, S., & Sadeghi, R. H. (2025). Recombinase Polymerase Amplification (RPA) as an Isothermal Molecular-Point of Care Test (IM-POCT) for Rapid Identification of P. aeruginosa Among Patients with Respiratory Infection. Molecular Biotechnology. https://doi.org/10.1007/s12033-025-01459-9
Vancouver
Azizian R, Jafari E, Pourakabri B, Mamishi S, Hosseinkhani S, Sadeghi RH. Recombinase Polymerase Amplification (RPA) as an Isothermal Molecular-Point of Care Test (IM-POCT) for Rapid Identification of P. aeruginosa Among Patients with Respiratory Infection. Molecular Biotechnology. 2025. doi:10.1007/s12033-025-01459-9
BibTeX
@article{Azizian2025,
author = {Azizian, Reza and Jafari, Erfaneh and Pourakabri, Babak and Mamishi, Setareh and Hosseinkhani, Saman and Sadeghi, Reihaneh Hosseinpour},
title = {Recombinase Polymerase Amplification (RPA) as an Isothermal Molecular-Point of Care Test (IM-POCT) for Rapid Identification of P. aeruginosa Among Patients with Respiratory Infection},
journal = {Molecular Biotechnology},
year = {2025},
doi = {10.1007/s12033-025-01459-9}
}
EUVIMED